Carefully Timed
A World First in Predictive Analytics
Our breakthrough technology is a world first predictive analytics tool that provides actionable insights to improve the health & well-being of everyone.
Leveraging proprietary immune mapping technology, our data indicates that we are able to predict the ideal time in future to administer medical treatments, vaccinations, surgical procedures, therapies, and general health and well-being practices.
Our unique discovery empowers us to identify optimal days and times to achieve the best possible outcomes in the shortest possible times and with the least risk.
Novel time-synchronized immune-guided partial tumor irradiation: Proof
of principle trial. (Oct 2024)
OUR RESEARCH
Faster, Less Toxic, and More Effective: A Holy Trinity in Palliative Radiotherapy
Time-Synchronized Immune-Guided Partial Tumor Irradiation: Proof-of-Principle Trial (NCT04168320) (Oct 2024)
Time-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment (Dec 2019)
Applications
Preventative Vaccinations
Accurate Diagnosis
Cancer Treatment
Physical Rehabiltation
Health & Wellbeing
Neurological Conditions
Surgical Procedures
Professional Sports
Our Team
Daniel Trenton Managing Director & Founder
Professor Kumar Visvanathan
Scientific advisory board member (Infectious Diseases)
Levent Shevki
Corporate Advisor
Luke Ashdown
Cofounder & COO
Martin Ashdown Chief Scientific Officer & Cofounder
Shane Ryan Strategic Partnerships & Clinical Access (Oncology)
Associate Professor Sid Baxi
Scientific advisory board member (Oncology)
Dr Slavisa Tubin
Scientific advisory board member (Oncology)
Dr David Speakman Chief Medical Officer (Oncology)
Aldo Rolfo Commercial Strategy & Patient Access
(Oncology)
Dr. Mark Cook
Scientific advisory board member (Neurology)